Latest News

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pentair To Contact Him Directly To Discuss Their Options If you purchased or acquired

Universal Display NASDAQ: OLED President and CEO Steve Abramson said the OLED industry's continued investment in new manufacturing capacity reflects panel makers' confidence in long-term adoption, eve

MTY Food Group offers resilient, recurring cash flows from a diversified, predominantly franchised portfolio of 90 brands, trading at a P/FCF below 7. I rate MTY as a Buy with a conservative fair valu

Cal-Maine Foods remains a Buy as valuation discounts its transformation toward value-added products despite weak egg prices. CALM is investing heavily in prepared foods and specialty eggs, targeting o

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intuit To Contact Him Directly To Discuss Their Options If you purchased or acquired

Federated Hermes US Strategic Dividend ETF remains rated 'hold' due to underperformance versus peers and concerns over quality and growth. FDV offers a 3.05% estimated dividend yield, but its high 0.5

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EquipmentShare To Contact Him Directly To Discuss Their Options If you purchased or a

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In First Solar To Contact Him Directly To Discuss Their Options If you purchased or acqu

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bloom Energy To Contact Him Directly To Discuss Their Options If you purchased or acq

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ZoomInfo To Contact Him Directly To Discuss Their Options If you purchased or acquire

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hub Group To Contact Him Directly To Discuss Their Options If you purchased or acquir

YETI Holdings remains a compelling buy after a post-earnings sell-off, with shares now trading within my fair value range of $40.57–$47.87. YETI continues to deliver strong fundamentals: 59% gross mar

Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, an

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquir

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Futu To Contact Him Directly To Discuss Their Options If you purchased or acquired se

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquir

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Blaize To Contact Him Directly To Discuss Their Options If you purchased or acquired

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rackspace To Contact Him Directly To Discuss Their Options If you purchased or acquir

Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in re

Harvard Management Company revealed a $2.2 billion SpaceX stake as university endowments benefit from early investments in Elon Musk's rocket company